[Image courtesy of PubChem]
Participants in a Phase 3 COVID-19 study who received the antiparasitic ivermectin fared about as well as those who got a placebo. Ivermectin recipients recovered in a median time of 12 days, while placebo recipients convalesced in 13 days on average.The data from the ongoing ACTIV-6 study were published in JAMA. The study authors concluded that ivermectin did not “significantly improve time to recovery.” The article concluded that the “findings do not support the use of ivermectin in patients with mild to moderate COVID-19.”
Across all arms, the study involved 1,591 vaccinated and unvaccinated participants with mild to moderate COVID-19.
Recipients in the ivermectin arm received 400 μg/kg of ivermectin for three consecutive days.
The ACTIV-6 study was performed when the delta and omicron variants were the main drivers of COVID-19 in…